Triciribine
(Synonyms: 曲西瑞宾,API-2; NSC 154020; TCN) 目录号 : GC15392
Triciribine是一种腺苷类似物,靶向抑制蛋白激酶B(Akt),IC50值为130nM,具有抗肿瘤活性。
Cas No.:35943-35-2
Sample solution is provided at 25 µL, 10mM.
Triciribine is an adenosine analog that targets protein kinase B (Akt) with an IC50 value of 130nM and has antitumor activity[1, 2]. Triciribine is a DNA synthesis inhibitor of HIV-1 with an IC50 value of 20nM[3].
In vitro, treatment of prostate cancer PC-3 cells with Triciribine (10μM) for 24h enhanced apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) and anti-CD95[4]. Treatment of bovine cumulus-oocyte complex (COC) with Triciribine (1μM) for 22h resulted in an increase in the rate of blastocyst formation and increased the in vitro yield of bovine embryos[5].
In vivo, treatment of C57BL/6 J mice with Triciribine (1, 2mg/kg/day) by intraperitoneal injection for 2 weeks significantly increased the level of low-density lipoprotein receptor (LDLR) in the liver of mice[6]. Triciribine (1mg/kg/day) was intraperitoneally injected into mice inoculated with GFP+ Huh7 cells for 14 days, which significantly inhibited the growth of tumors in mice and exerted a synergistic effect when combined with rosiglitazone[7].
References:
[1] Barrichon M, Hadi T, Wendremaire M, et al. EXPRESSION OF CONCERN: Dose‐dependent biphasic leptin‐induced proliferation is caused by non‐specific IL‐6/NF‐κB pathway activation in human myometrial cells[J]. British Journal of Pharmacology, 2015, 172(12): 2974-2990.
[2] Garrett C R, Coppola D, Wenham R M, et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT[J]. Investigational new drugs, 2011, 29: 1381-1389.
[3] KUCERA L S, IYER N P, PUCKETT S H, et al. Activity of triciribine and triciribine-5′-monophosphate against human immunodeficiency virus types 1 and 2[J]. AIDS research and human retroviruses, 1993, 9(4): 307-314.
[4] Dieterle A, Orth R, Daubrawa M, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL‐induced apoptosis[J]. International journal of cancer, 2009, 125(4): 932-941.
[5] Curcio A G, Ribeiro T I S, Gomes H F, et al. Increased in vitro production of bovine embryos resulting from oocyte maturation in the presence of triciribine, a specific inhibitor of AKT[J]. Theriogenology, 2025, 231: 222-227.
[6] Bjune K, Wierød L, Naderi S. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA[J]. Scientific Reports, 2018, 8(1): 16174.
[7] Liu L, Yang Z, Xu Y, et al. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells[J]. PloS one, 2013, 8(8): e73038.
Triciribine是一种腺苷类似物,靶向抑制蛋白激酶B(Akt),IC50值为130nM,具有抗肿瘤活性[1, 2]。Triciribine是HIV-1的DNA合成抑制剂,IC50值为20nM[3]。
在体外,Triciribine(10μM)处理前列腺癌PC-3细胞24h,增强了TNF相关凋亡诱导配体(TRAIL)和抗CD95诱导的细胞凋亡[4]。Triciribine(1μM)处理牛卵丘-卵母细胞复合物(COC)22h,导致囊胚生成速率增加,增加了牛胚胎的体外产量[5]。
在体内,Triciribine(1, 2mg/kg/day)通过腹腔注射处理C57BL/6 J小鼠2周,显著增加了小鼠体内肝脏内低密度脂蛋白受体(LDLR)的水平[6]。Triciribine(1mg/kg/day)通过腹腔注射治疗接种GFP+ Huh7细胞的小鼠14天,显著抑制了小鼠体内肿瘤的生长,与罗格列酮联合治疗发挥协同效应[7]。
Cell experiment [1]: | |
Cell lines | PC-3 cells |
Preparation Method | PC-3 cells were treated with TNF-related apoptosis inducing ligand (TRAIL) (0.1, 1, 10, or 40ng/mL) or anti-CD95 (0.1, 1, 10, or 100ng/mL) in the presence or absence of either Triciribine (10μM) or Akti-1/2 (10μM) for 24h. As control PC-3 cells were treated with Triciribine (0.1, 1, 10 or 40μM) or Akti-1/2 (0.1, 1, 10 or 40μM). Apoptosis was assessed by propidium iodide staining of hypodiploid apoptotic nuclei and flow cytometry. |
Reaction Conditions | 10μM; 24h |
Applications | Triciribine amplifies TRAIL-induced and anti-CD95-induced apoptosis in PC-3 cells. |
Animal experiment [2]: | |
Animal models | C57BL/6 J mice |
Preparation Method | Mice were separated into three treatment groups each consisting of 4 mice. One group received i.p. Triciribine at 1mg/kg daily. A second group received daily i.p. injections of Triciribine at 2mg/kg. A third group was administered daily i.p. injections of vehicle (0.1% DMSO in PBS). Injection volumes were 100µL per mouse. Two weeks later, mice were sacrificed and livers were processed into a powder by grinding in liquid nitrogen, lysed in RIPA buffer and then analyzed by Western blotting. |
Dosage form | 1, 2mg/kg/day; 2 weeks; i.p. |
Applications | Treatment of mice with either doses of Triciribine for two weeks significantly increased the levels of hepatic Low-density lipoprotein receptor (LDLR). |
References: |
Cas No. | 35943-35-2 | SDF | |
别名 | 曲西瑞宾,API-2; NSC 154020; TCN | ||
化学名 | (2R,3R,4S,5R)-2-(3-amino-5-methyl-1,4,5,6,8-pentaazaacenaphthylen-1(5H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | ||
Canonical SMILES | [H][C@](N1C(N=C([H])N=C2N(C([H])([H])[H])N=C3N([H])[H])=C2C3=C1[H])([C@]4([H])O[H])O[C@@](C([H])([H])O[H])([H])[C@@]4([H])O[H] | ||
分子式 | C13H16N6O4 | 分子量 | 320.3 |
溶解度 | ≥ 118.4mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.1221 mL | 15.6104 mL | 31.2207 mL |
5 mM | 0.6244 mL | 3.1221 mL | 6.2441 mL |
10 mM | 0.3122 mL | 1.561 mL | 3.1221 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet